Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) reported its financial results for the first quarter of 2026, revealing a revenue of $778,000, a significant increase from zero revenue in the same period of 2025. This revenue is attributed to the sales of fire safety equipment and services from its newly acquired subsidiary, Fitters Sdn. Bhd., which was integrated into the company following its acquisition in September 2025. The company’s operating expenses for the quarter were $1.0 million, down from $4.2 million in the prior year, primarily due to the absence of one-time costs associated with previous changes in control and a reduction in stock-based compensation expenses.

The company’s net loss for the quarter was $197,000, a notable improvement compared to a net loss of $81,000 in the first quarter of 2025. The decrease in losses was driven by lower general and administrative expenses, which fell by approximately $3.8 million year-over-year. The company reported a gross margin of approximately 18% on its fire safety product sales, with cost of sales amounting to $635,000 for the quarter. The company’s accumulated deficit stood at $454.6 million as of March 31, 2026.

In terms of operational changes, Bio Green Med Solution has shifted its focus from biopharmaceuticals to fire safety products, following the liquidation of its UK subsidiary, Cyclacel Limited, in January 2025. This strategic pivot has led to the deconsolidation of Cyclacel Limited's financial results, resulting in a gain of approximately $5.0 million recognized in the previous fiscal year. The company has also engaged in various financing activities, including the issuance of preferred stock, which has provided necessary liquidity to support its operations.

As of March 31, 2026, the company had cash and cash equivalents of $3.3 million, which it anticipates will sustain its operations into the fourth quarter of 2026. However, the company has expressed substantial doubt about its ability to continue as a going concern, citing the need for additional capital to fund its operations. The management is exploring various strategic alternatives, including potential mergers or acquisitions, to secure necessary funding. The company’s future revenue growth is expected to be driven by the expansion of its fire safety product offerings, particularly in the rapidly growing market in Southern Malaysia.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines targeting cell cycle, epigenetics, and mitosis biology. Its lead program, plogo, is a PLK1 inhibitor aimed at solid tumors and hematological malignancies. The company emphasizes targeted, oral therapies with potential for improved safety and efficacy, seeking strategic partnerships while retaining global rights to its drug candidates.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.